1. Home
  2. RELI vs SNPX Comparison

RELI vs SNPX Comparison

Compare RELI & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RELI
  • SNPX
  • Stock Information
  • Founded
  • RELI 2013
  • SNPX 2012
  • Country
  • RELI United States
  • SNPX United States
  • Employees
  • RELI N/A
  • SNPX N/A
  • Industry
  • RELI Specialty Insurers
  • SNPX Medicinal Chemicals and Botanical Products
  • Sector
  • RELI Finance
  • SNPX Health Care
  • Exchange
  • RELI Nasdaq
  • SNPX Nasdaq
  • Market Cap
  • RELI 3.5M
  • SNPX 3.1M
  • IPO Year
  • RELI N/A
  • SNPX N/A
  • Fundamental
  • Price
  • RELI $1.47
  • SNPX $2.41
  • Analyst Decision
  • RELI
  • SNPX Strong Buy
  • Analyst Count
  • RELI 0
  • SNPX 1
  • Target Price
  • RELI N/A
  • SNPX $14.00
  • AVG Volume (30 Days)
  • RELI 41.1K
  • SNPX 19.8K
  • Earning Date
  • RELI 07-24-2025
  • SNPX 05-15-2025
  • Dividend Yield
  • RELI N/A
  • SNPX N/A
  • EPS Growth
  • RELI N/A
  • SNPX N/A
  • EPS
  • RELI N/A
  • SNPX N/A
  • Revenue
  • RELI $14,208,143.00
  • SNPX N/A
  • Revenue This Year
  • RELI N/A
  • SNPX N/A
  • Revenue Next Year
  • RELI N/A
  • SNPX N/A
  • P/E Ratio
  • RELI N/A
  • SNPX N/A
  • Revenue Growth
  • RELI 2.40
  • SNPX N/A
  • 52 Week Low
  • RELI $0.97
  • SNPX $1.84
  • 52 Week High
  • RELI $18.53
  • SNPX $5.05
  • Technical
  • Relative Strength Index (RSI)
  • RELI 68.56
  • SNPX 49.39
  • Support Level
  • RELI $1.29
  • SNPX $2.51
  • Resistance Level
  • RELI $1.56
  • SNPX $2.76
  • Average True Range (ATR)
  • RELI 0.09
  • SNPX 0.18
  • MACD
  • RELI 0.03
  • SNPX 0.03
  • Stochastic Oscillator
  • RELI 80.00
  • SNPX 45.10

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About SNPX Synaptogenix Inc.

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Share on Social Networks: